Skip to main content
Premium Trial:

Request an Annual Quote

Trace Genomics Raises $13M in Series A Financing Round

NEW YORK (GenomeWeb) – Trace Genomics announced today that it has raised $13 million in a Series A funding round.

The round was led by Stage 1 Ventures and also included participation from Viking Global Investors AgFunder and other investors.

The San Francisco-based firm's technology uses high-throughput DNA sequencing, artificial intelligence, and a database of microbial species living in soil to identify and profile the soil microbiome. The company raised $4 million in a seed funding round in 2016. Trace noted that this round brings its total capital raised to date to more than $19 million.

According to Trace, its microbiome assay interprets soil health and disease risk indicators in soil samples, offering insights for growers as to how to more efficiently use nutrients, reduce costs for soil maintenance, reduce crop disease risk, and which seeds, rotations, or biological agents will work best for their particular soil.

"Trace Genomics has developed a highly scalable software and analytics platform to quantify soil productivity and offer actionable insights never before captured," Stage 1 Operating Partner Joseph Pianelli said in a statement.

In the next year, Trace said it plans to expand to the corn and soybean markets with its ability to process more than a thousand soil samples a week across several geographies and soil types.

"Measuring the soil biome is the critical first step in optimizing the natural functions present in our soils today, so we can be more precise and economical in choosing seed, nutrients, and other inputs," Trace Genomics President and Cofounder Poornima Parameswaran added.  

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more